Unlocking the power of cannabinoids for treatment of serious neurological and inflammatory conditions

Vitality Biopharma has developed a new class of cannabinoid prodrugs, known as cannabosides, which upon ingestion can enable the selective delivery of THC and cannabidiol (CBD) to the gastrointestinal tract.

Cannabosides reduce or avoid psychoactive side effects through targeted prodrug technology

Meeting Pharmaceutical Market Demands

Vitality is developing proprietary cannabinoid pharmaceuticals that are compliant with FDA and DEA regulations. Oral cannabinoid pharmaceuticals are a convenient and desirable option for patients and physicians, and they could help realize the full therapeutic potential of cannabinoid medicines.

Learn More

A Low-Cost, Low-Risk Regulatory Strategy

Oral prodrugs enable a regulatory strategy with lower risk that is akin to specialty pharmaceutical development. The company benefits from existing clinical studies of cannabinoids demonstrating their effectiveness in treating in IBD, NBS, MS, neuropathic pain, and additional disease indications.

Learn More

Our mission

Vitality’s operations include federally-compliant cannabinoid drug development and the launch of a specialty care treatment network in the United States focused on the reduction of opioid dependence.